359 related articles for article (PubMed ID: 11433225)
61. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies.
Pouplard C; Leroux D; Regina S; Rollin J; Gruel Y
Thromb Haemost; 2010 Jan; 103(1):145-50. PubMed ID: 20062918
[TBL] [Abstract][Full Text] [Related]
62. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia.
Gobbi G; Mirandola P; Tazzari PL; Talarico E; Caimi L; Martini G; Papa S; Conte R; Manzoli FA; Vitale M
Cytometry B Clin Cytom; 2004 Mar; 58(1):32-8. PubMed ID: 14994373
[TBL] [Abstract][Full Text] [Related]
63. Atomic description of the immune complex involved in heparin-induced thrombocytopenia.
Cai Z; Yarovoi SV; Zhu Z; Rauova L; Hayes V; Lebedeva T; Liu Q; Poncz M; Arepally G; Cines DB; Greene MI
Nat Commun; 2015 Sep; 6():8277. PubMed ID: 26391892
[TBL] [Abstract][Full Text] [Related]
64. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia.
Perdomo J; Leung HHL; Ahmadi Z; Yan F; Chong JJH; Passam FH; Chong BH
Nat Commun; 2019 Mar; 10(1):1322. PubMed ID: 30899022
[TBL] [Abstract][Full Text] [Related]
65. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
[TBL] [Abstract][Full Text] [Related]
66. Anti-PF4/heparin antibodies are increased in hospitalized patients with bacterial sepsis.
Maharaj S; Chang S
Thromb Res; 2018 Nov; 171():111-113. PubMed ID: 30273811
[TBL] [Abstract][Full Text] [Related]
67. Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.
Januzzi JL; Jang IK
J Thromb Thrombolysis; 2000 Nov; 10 Suppl 1():7-11. PubMed ID: 11155189
[TBL] [Abstract][Full Text] [Related]
68. The pathophysiology of immune-mediated heparin-induced thrombocytopenia.
Reilly RF
Semin Dial; 2003; 16(1):54-60. PubMed ID: 12535302
[TBL] [Abstract][Full Text] [Related]
69. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
Rauova L; Zhai L; Kowalska MA; Arepally GM; Cines DB; Poncz M
Blood; 2006 Mar; 107(6):2346-53. PubMed ID: 16304054
[TBL] [Abstract][Full Text] [Related]
70. Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review.
Shih AW; Sheppard JI; Warkentin TE
Thromb Haemost; 2017 Oct; 117(10):1868-1874. PubMed ID: 28837208
[TBL] [Abstract][Full Text] [Related]
71. P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment.
Papalambros E; Sigala F; Travlou A; Bastounis E; Mirilas P
J Am Coll Surg; 2004 Jul; 199(1):69-77. PubMed ID: 15217633
[TBL] [Abstract][Full Text] [Related]
72. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.
Blank M; Shoenfeld Y; Tavor S; Praprotnik S; Boffa MC; Weksler B; Walenga MJ; Amiral J; Eldor A
Int Immunol; 2002 Feb; 14(2):121-9. PubMed ID: 11809731
[TBL] [Abstract][Full Text] [Related]
73. Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.
Leroux D; Canépa S; Viskov C; Mourier P; Herman F; Rollin J; Gruel Y; Pouplard C
J Thromb Haemost; 2012 Mar; 10(3):430-6. PubMed ID: 22235911
[TBL] [Abstract][Full Text] [Related]
74. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: Atypical clinical features with heparin-dependent platelet activating antibodies.
Okata T; Miyata S; Miyashita F; Maeda T; Toyoda K
Platelets; 2015; 26(6):602-7. PubMed ID: 25383922
[TBL] [Abstract][Full Text] [Related]
75. PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses.
Haile LA; Rao R; Polumuri SK; Arepally GM; Keire DA; Verthelyi D; Sommers CD
Thromb Res; 2017 Nov; 159():39-47. PubMed ID: 28968537
[TBL] [Abstract][Full Text] [Related]
76. Management of heparin-induced thrombocytopenia.
Warkentin TE; Greinacher A
Curr Opin Hematol; 2016 Sep; 23(5):462-70. PubMed ID: 27380556
[TBL] [Abstract][Full Text] [Related]
77. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.
Francis JL
Semin Thromb Hemost; 2004 Jun; 30(3):359-68. PubMed ID: 15282659
[TBL] [Abstract][Full Text] [Related]
78. Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients.
Boonyawat K; Angchaisuksiri P; Aryurachai K; Chaiyaroj S; Ahmadi Z; Chong BH
Thromb Res; 2014 Nov; 134(5):957-62. PubMed ID: 25204999
[TBL] [Abstract][Full Text] [Related]
79. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies--distinguishing "signal" from "noise".
Warkentin TE
Thromb Haemost; 2008 Oct; 100(4):523-4. PubMed ID: 18841271
[No Abstract] [Full Text] [Related]
80. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels.
Baroletti S; Hurwitz S; Conti NA; Fanikos J; Piazza G; Goldhaber SZ
Am J Med; 2012 Jan; 125(1):44-9. PubMed ID: 22075045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
